Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world observational study of eribulin mesylate in locally advanced or metastatic breast cancer
ChiCTR2100044109Phase 4Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eribulin in breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Progression-free survival and Objective response rate. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100044109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044109.